Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes.

Published byValerie Spencer Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes."— Presentation transcript:

1 Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials The frequency of reporting of primary and secondary outcome measures in 58 MS DMT clinical trials used to inform MS DMT guideline development are depicted (ordered as in Figure 1). QoL = quality of life. Published with permission Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 2018;90;777–788. doi: /WNL Gregory S. Day et al. Neurol Clin Pract 2018;8: © 2018 American Academy of Neurology

Download ppt "Figure 2 Primary and secondary outcomes reported in multiple sclerosis (MS) disease-modifying therapy (DMT) clinical trials Primary and secondary outcomes."

Similar presentations

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.

Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
Outcome Measures for Individuals With Multiple Sclerosis: Recommendations From the American Physical Therapy Association Neurology Section Task Force by.

Outcome Measures for Individuals With Multiple Sclerosis: Recommendations From the American Physical Therapy Association Neurology Section Task Force by.
Figure Flow of funds for a 340B agreement for fingolimod

Figure Flow of funds for a 340B agreement for fingolimod
Figure 1 Perivenous distribution of multiple sclerosis lesions

Figure 1 Perivenous distribution of multiple sclerosis lesions
Figure EDSS, FS scores, and Modified MSFC scores

Figure EDSS, FS scores, and Modified MSFC scores
Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol
Figure 3 Proportion of patients for whom NEDA

Figure 3 Proportion of patients for whom NEDA
Figure 3 Archetypal MS clinical course depicted over 20 years

Figure 3 Archetypal MS clinical course depicted over 20 years
Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.

Figure 2 Disease progression slowed during each round of Treg infusions and correlated with increased Treg suppressive function Disease progression slowed.
Figure 1 Patient flow diagram

Figure 1 Patient flow diagram
Figure 1 Clinical correlates of neurodegeneration in MS

Figure 1 Clinical correlates of neurodegeneration in MS
Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.

Figure 1 Outcomes of greatest importance to selection of a multiple sclerosis (MS) disease-modifying therapy (DMT), as defined by persons with MS and panelists.
Figure 2 Provider decision algorithm: Considerations in retirement discussion and recommendation Provider decision algorithm: Considerations in retirement.

Figure 2 Provider decision algorithm: Considerations in retirement discussion and recommendation Provider decision algorithm: Considerations in retirement.
Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.

Figure 1 MOR103 sequential-dose trial flowchart of study population with multiple sclerosis aPatients received 2 doses of study drug before trial withdrawal.
Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)

Figure 1 8-Iso-PGF2α levels in CSF of patients with MS and controlsCSF 8-iso-prostaglandin F2α (8-iso-PGF2α) levels were estimated using an ELISA. (A)
Figure 2 Forest plots for subgroup analyses

Figure 2 Forest plots for subgroup analyses
Figure 2. ROC curves for different group comparisons

Figure 2. ROC curves for different group comparisons
Figure 3 Temporal trends in FALS incidence

Figure 3 Temporal trends in FALS incidence
Figure 1 Characteristics of the German National MS Cohort

Figure 1 Characteristics of the German National MS Cohort
SPIRIT diagram. SPIRIT diagram. The figure details the timing of enrollment activities, intervention allocation, and assessments of outcomes over the course.

SPIRIT diagram. SPIRIT diagram. The figure details the timing of enrollment activities, intervention allocation, and assessments of outcomes over the course.

Similar presentations

Ads by Google